These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 33544355)

  • 21. Insulin degludec versus insulin glargine, both once daily as add-on to existing orally administered antidiabetic drugs in insulin-naive Japanese patients with uncontrolled type 2 diabetes: subgroup analysis of a pan-Asian, treat-to-target phase 3 trial.
    Osonoi T; Onishi Y; Nishida T; Hyllested-Winge J; Iwamoto Y
    Diabetol Int; 2016 Jun; 7(2):141-147. PubMed ID: 30603257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.
    Lankisch MR; Ferlinz KC; Leahy JL; Scherbaum WA;
    Diabetes Obes Metab; 2008 Dec; 10(12):1178-85. PubMed ID: 19040645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are diabetes management guidelines applicable in 'real life'?
    Viana LV; Leitão CB; Grillo Mde F; Rocha EP; Brenner JK; Friedman R; Gross JL
    Diabetol Metab Syndr; 2012 Nov; 4(1):47. PubMed ID: 23171858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Patients with T2D Uncontrolled on NPH or Premixed Insulins as Part of Routine Clinical Practice in Bulgaria: ToUPGRADE Study.
    Kamenov Z; Pehlivanova V; Kuneva T; Kirilov K; Bobeva R; Stoykova J; Mihalevska S
    Diabetes Ther; 2021 Mar; 12(3):913-930. PubMed ID: 33604804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.
    Bucello S; Annovazzi P; Ragonese P; Altieri M; Barcella V; Bergamaschi R; Bianchi A; Borriello G; Buscarinu MC; Callari G; Capobianco M; Capone F; Cavalla P; Cavarretta R; Cortese A; De Luca G; Di Filippo M; Dattola V; Fantozzi R; Ferraro E; Filippi MM; Gasperini C; Grimaldi LME; Landi D; Re ML; Mallucci G; Manganotti P; Marfia GA; Mirabella M; Perini P; Pisa M; Realmuto S; Russo M; Tomassini V; Torri-Clerici VLA; Zaffaroni M; Zuliani C; Zywicki S; Filippi M; Prosperini L
    J Neurol; 2021 Aug; 268(8):2922-2932. PubMed ID: 33616742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World Analysis of Rapid-Acting Insulin Analog Use and Its Blood Glucose Lowering Effect in Patients with Type 2 Diabetes Mellitus: Results from PASSION Disease Registry in Korea.
    Kim HS; Yu JM; Jang HC; Choi EK; Park JH; Shon HS; Chung CH; Park KG; Cho JH; Kim W; Lee KH; Lee JH; Yoo SJ
    Diabetes Metab Syndr Obes; 2022; 15():1495-1503. PubMed ID: 35591905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S Study.
    Seufert J; Pfohl M; Borck A; Bramlage P; Siegmund T
    Diabetes Ther; 2021 Mar; 12(3):749-764. PubMed ID: 33544356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
    Tonneijck L; Muskiet MHA; Smits MM; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2017 Dec; 19(12):1669-1680. PubMed ID: 28449402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK.
    Davies M; Evans R; Storms F; Gomis R; Khunti K
    Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short Term Efficacy and Safety of Insulin Glargine in Type 2 Diabetes Inadequately Controlled with Single or Two Oral Agents: A Prospective, Open Label Study.
    Aggarwal A; Wadhwa R
    J Clin Diagn Res; 2017 Jul; 11(7):OC21-OC24. PubMed ID: 28892956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and Safety of Insulin Glulisine When Initiating Supplementary Prandial Insulin Treatment (SIT) in Insulin-Naïve Patients with Type 2 Diabetes: The Observational IGLU-SIT Study.
    Pfohl M; Seufert J; Borck A; Bramlage P; Siegmund T
    Diabetes Ther; 2021 Mar; 12(3):733-747. PubMed ID: 33544355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes.
    Nicolucci A; Ceriello A; Di Bartolo P; Corcos A; Orsini Federici M
    Diabetes Ther; 2020 Mar; 11(3):573-584. PubMed ID: 31873857
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.